Duchenne approval exposes FDA rift over Sarepta gene therapy
BioPharma Drive: Drug Pricing
JUNE 21, 2024
Peter Marks’ decision to override the objections of agency staff and broaden use of Elevidys could have a “lasting impact” on gene therapy as well as the FDA, one analyst wrote.
Let's personalize your content